Marinus Pharma (MRNS) Tops Q2 EPS by 4c

Marinus Pharma (NASDAQ: MRNS) reported Q2 EPS of ($0.65), $0.04 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $1.91 million versus the consensus estimate of $2.7 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Piper Sandler picks Payments and Consumer Finance winners as multiples reset
• RUM Group reports GPU use surge and $270M in contracted revenue